NIHR CRSU

COMPLEX REVIEWS SUPPORT UNIT

University of Glasgow · UNIVERSITY OF LEICESTER · LONDON SCHOOL of HYGIENE &TROPICAL MEDICINE · FUNDED BY NIHR | National Institute for Health Research

MetaInsight COVID-19 app
https://crsu.shinyapps.io/metainsightcovid/

Network Meta-Analysis of Pharmacological treatments for COVID 19: Tool for exploration, re-analysis, sensitivity analysis, and interrogation of data from living systematic reviews

Speaker: Yiqiao Xin

MetaInsight: COVID-19 app

Network Meta-Analysis of Pharmacological treatments for COVID 19: Tool for exploration, re-analysis, sensitivity analysis, and interrogation of data from living systematic reviews

- **Link: https://crsu.shinyapps.io/metainsightcovid/**

- Rationale: duplicated work on COVID-19 evidence synthesis

- Built on CRSU MetaInsight (http://www.nihrcrsu.org/guidance/apps/)

- Data from the Living mapping and living systematic review of COVID-19 studies (covid-nma.com)

- living analysis platform

- App brief demo 👉

- New evidence added weekly through a semi-automated process

Pharmacological treatments
All-cause mortality D14-28

Study	Follow-up days	Intervention 1	Intervention 2	r1/N1	r2/N2	A	B	C	D	E	Overall		Risk Ratio [95% CI]
Mild													
Skipper CP, 2020	14	Hydroxychloroquine 600 mg*	Placebo	1/244	1/247	🟨	🟨	🟨	🟩	🟩	🟨	0.13%	1.01 [0.06, 16.09]
Mild													
Mitja O, 2020	28	Hydroxychloroquine 400 mg*	Standard care	0/169	0/184	🟩	🟨	🟩	🟩	🟨	🟨		
Mild population													1.01 [0.06, 16.09]
Mild/moderate													
Chen CP, 2020	14	Hydroxychloroquine 400mg/day*	Standard care	0/19	0/11	🟨	🟩	🟩	🟩	🟨	🟨		
Mild/moderate													
Cavalcanti AB, 2020	15	Hydroxychloroquine 800 mg	Standard care	7/221	6/229	🟩	🟥	🟩	🟩	🟩	🟩	0.89%	1.21 [0.41, 3.54]
Moderate													
Chen L, 2020	28	Hydroxychloroquine 400 mg	Standard care	0/28	0/14	🟥	🟨	🟥	🟩	🟩	🟥		
Moderate													
Chen J, 2020	14	Hydroxychloroquine 400 mg	Standard care	0/15	0/15	🟥	🟩	🟩	🟩	🟨	🟥		
Mild to severe													
Tang W, 2020	20	Hydroxychloroquine 800 mg*	Standard care	0/75	0/75	🟨							
Mild to critical													
Horby P, 2020	28	Hydroxychloroquine 800 mg*	Standard care	418/1561	788/3155	🟩							
Mixed population													

Heterogeneity: $Q = 0.28$, $p = 1.00$; $I^2 = 0.0\%$; $\tau^2 = 0.00$

(*different loading dose)

Risk of bias ratings:
- 🟩 Low Risk of Bias
- 🟨 Some Concerns
- 🟥 High Risk of Bias

Risk of Bias Domains:
A: Bias due to randomization
B: Bias due to deviation from intended intervention
C: Bias due to missing data
D: Bias due to outcome measurement
E: Bias due to selection of reported result

Intervention 1 better   Intervention 2 b

0.14   1.95

Risk Ratio

Raspberry Pi – Raspberry Pi
raspberrypi.org

MetaInsight: COVID-19 app

Network Meta-Analysis of Pharmacological treatments for COVID 19: Tool for exploration, re-analysis, sensitivity analysis, and interrogation of data from living systematic reviews

- **Link: https://crsu.shinyapps.io/metainsightcovid/**

- Rationale: duplicated work on COVID-19 evidence synthesis

- Built on CRSU MetaInsight (http://www.nihrcrsu.org/guidance/apps/)

- Data from the Living mapping and living systematic review of COVID-19 studies (covid-nma.com)

- living analysis platform

- App brief demo 👉

- New evidence added weekly through a semi-automated process

- **Open science**

- **Interactive reporting format for any NMA**

Raspberry Pi – Raspberry Pi
raspberrypi.org

Thank you for listening!

Alex Sutton   ajs22@leicester.ac.uk
Yiqiao Xin   Yiqiao.Xin@glasgow.ac.uk
Clareece Nevill   clareece.nevill@leicester.ac.uk

Contributors

Yiqiao Xin [1], Clareece Nevill [2], Janion Nevill, Ewan Gray [3], Nicola Cooper [2], Rhiannon K Owen [2], Naomi Bradbury [4], and Alex Sutton [2].

Steering committee

Olivia Wu [1], Neil Hawkins [1], Suzanne Freeman [2], Peter Langhorne [5], Terry Quinn [5], and Moira Sim [1]

Affiliations

1 NIHR Complex Review Support Unit, Health Technology Assessment and Health Economics (HEHTA), Institute of Health and Wellbeing, University of Glasgow, UK.

2 NIHR Complex Review Support Unit, Department of Health Sciences, University of Leicester, UK.

3 Edinburgh Clinical Trials Unit (ECTU), University of Edinburgh, UK.

4 Zeeman Institute: Systems Biology and Infectious Disease Epidemiology Research (SBIDER), School of Life Sciences, University of Warwick, Coventry, UK.

5 Institute of Cardiovascular & Medical Sciences, University of Glasgow, UK.